Oral Vinorelbine and Cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral Vinorelbine and Cispalatine plus best supportive care or best supportive care alone in stage III Non Small Cell Lung Cancer (NSCLC): rand
Oral Vinorelbine and Cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral Vinorelbine and Cispalatine plus best supportive care or best supportive care alone in stage III Non Small Cell Lung Cancer (NSCLC): rand
Oral Vinorelbine and Cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral Vinorelbine and Cispalatine plus best supportive care or best supportive care alone in stage III Non Small Cell Lung Cancer (NSCLC): randomized Phase III study
Statut
Status :
Terminé prématurément
Type d'étude
Phase III
Age Min.
18
Ans
Age Max.
75
Ans
Genre
Tous
Aire thérapeutique :
Oncologie
Maladie :
Cancer du poumon métastatique non à petites cellules
Traitement :
Vinorelbine (Navelbine® Oral)
Phase :
Phase III
Date de début de l'étude :
02 Mai 2005
End date :
09 Mai 2012
Identifiant de l'essai :
PM0259 CA 304 J1
Identifiant EudraCT/CTIS :
2004-005135-26
Envoyer par email